New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
September 30, 2021 08:30 ET
|
Arcutis Biotherapeutics, Inc.
Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as Phase 2 studies in seborrheic dermatitis and scalp and body...
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
September 28, 2021 16:05 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Appointment of Keith Leonard to Board of Directors
September 02, 2021 16:10 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 16:05 ET
|
Arcutis Biotherapeutics, Inc.
Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of...
Arcutis Announces Additions to its Investor Relations and Communications Team
August 02, 2021 16:05 ET
|
Arcutis Biotherapeutics, Inc.
Eric McIntyre joins as Head of Investor RelationsAmanda Sheldon joins as Head of Corporate Communications WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics,...
Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psoriasis
July 21, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
The majority of patients with psoriasis have mild or moderate levels of diseaseThe new method, PASI-high discrimination (PASI-HD), is designed for use in clinical trials evaluating novel topical...
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
July 12, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Topical roflumilast potential “Best-in-Class” topical PDE4 inhibitorSeborrheic dermatitis affects 10 million patients in the U.S.Potential first new topical treatment for seborrheic dermatitis in...
Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo
July 01, 2021 06:00 ET
|
Arcutis Biotherapeutics, Inc.
Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligoCompany progressing new formulation with goal of greater drug...
Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies
June 23, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...
Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors
June 09, 2021 16:01 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments...